Sacnite Albarran

8 years in clinical research filling positions as a Clinical Data Associate, Sr. Clinical Data Associate, Lead Clinical Data Manager where my responsibilities covered; however were not limited to: Operational experience in Data Management (DM) that has spanned the full duration of studies, from study start-up to database lock on various global/multi-national studies (Phase I, II, III) across USA, South America, United Kingdom, Europe, Asia, India, Japan and Australia with significant experience working on Chronic Lymphocytic Leukemia, Influenza A (H1N1), Diabetic Macular Edema, Solid Tumor Configuration, Alzheimer's Disease, Postherpetic Neuralgia studies. On 30 October 2020 I took on the responsibilities of a Data Team Lead (DTL). The responsibilities of a DTL include but are not limited to: independently manage end-to-end delivery of data management services for projects, ensuring quality deliverables on time and within budget; providing comprehensive data management expertise to the Clinical Data Management (CDM) team; provide leadership and vision to the team in the areas of project planning, execution, and close-out; financial management; communications; and milestone deliverables to ensure high quality data management products that meet the customer needs.

• 11/2010, CINVESTAV, Mexico, Doctor of Philosophy, Neurosciences-Parkinson's disease, Attended - not Completed
• 11/2007, Chemistry and Biological Research Institute, UMSNH - Mexico, Mexico, Master of Science, Experimental Biology, Completed
• 06/2006, School of Chemistry and Pharmacology, UMSNH - Mexico, Mexico, Bachelor of Pharmacy, Pharmacology, Completed

• Phase 2, Hypertriglyceridemia, Other, 5, 35, 320, Lead Data Manager, Database Build, DM activities during start up. EDC updates per Protocol Amendments (CRFs updates).
• Phase 2, Dyslipidemia, Other, 5, 25, 180, Lead Data Manager, Database build, DM activities during start up. EDC updates for Protocol Amendments (CRFs updates).
• Phase 3, Myelofibrosis, Small Molecule (Kinase Inhibitor), 16, 136, 310, Lead Data Manager, All DM functional lead activities, from database build, UT, DM metrics, development and maintenance of DM Project Documentation, Data Review listings specifications, coordinate with the EDC programmer for Protocol Amendment updates in EDC. Query management, Data Reconciliations.
• Phase 3, Fabry's Disease, Rare Diseases, Biosimilars, 1, 5, 30, Lead Data Manager, DM functional lead activities, from database build, UT, DM metrics, development and maintenance of DM Project Documentation, Data Review listings specifications, coordinate with the EDC programmer for Protocol Amendment updates in EDC. Query management, Data Reconciliations.
• Phase 1, Solid Tumor Configuration, Chemotherapy, 3, 30, 300, Lead Data Manager, DM functional lead activities, from database build, UT, DM metrics, development and maintenance of DM Project Documentation, Data Review listings specifications, coordinate with the EDC programmer for Protocol Amendment updates in EDC. Query management, Data Reconciliations.
• Phase 3, Malignant Tumor of Ovary, Critical / Trauma Care, Chemotherapy, 7, 250, 418, Clinical Data Manager, All DM functional lead activities, from database updates, UT, DM metrics, development and maintenance of DM Project Documentation, Data Review listings specifications, coordinate with the EDC programmer for Protocol Amendment updates in EDC. Query management, Data Reconciliations.

• Neurology, Parkinson's Disease, Investigational Laboratory Research (Pre-clinical study)
• Alzheimer's Disease, Clinical Data Reviewer
• Narcolepsy, Clinical Data Reviewer
• Endocrinology, Diabetes Mellitus Type 2, Investigational Laboratory Research (Pre-clinical study)
• Cardiovascular, Dyslipidemia, Lead Clinical Data Manager, Hypertriglyceridemia
• Infectious Disease, Influenza A (H1N1), Lead Clinical Data Reviewer
• Dermatology, Postherpetic Neuralgia, Clinical Data Reviewer
• Ophthalmology, Diabetic Macular Edema, Lead Clinical Data Reviewer
• Other, Fabry's Disease, Lead Clinical Data Manager
• Oncology, Chronic Lymphocytic Leukemia, Lead Clinical Data Manager Backup, Solid Tumor Configuration, Lead Clinical Data Manager Backup Lead Clinical Data Manager, Malignant Tumor of Ovary, Lead Clinical Data Manager

• Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects by Sacnité Albarrán-Bravo, José Arturo Ávalos-Fuentes, Hernán Cortés, Marina Rodriguez-Sánchez, Norberto Leyva-García, Claudia Rangel-Barajas, David Erlij and Benjamín Florán. Biomolecules 2019, 9(9), 431; https://doi.org/10.3390/biom9090431
• Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca2 + dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat by Arturo Avalos-Fuentes, Sacnité Albarrán-Bravo, Santiago Loya-Lopéz, Hernán Cortés, Sergio Recillas-Morales, Jonathan J. Magaña, Francisco Paz-Bermúdez, Claudia Rangel-Barajas, Jorge Aceves, David Erlij, Benjamín Florán. Neurobiology of Disease, Volume 74, February 2015, Pages 336-346.
• Pathophysiology of L-Dopa Induced Dyskinesia ? Changes in D1/D3 Receptors and Their Signaling Pathway" "A Synopsis of Parkinson's Disease by Sacnité Albarrán-Bravo, Claudia Rangel-Barajas and Benjamín Florán. IntechOpen. Submitted: September 12th 2013Reviewed: September 20th 2013Published: March 26th 2014. DOI: 10.5772/57102

DIACR Qualified Clinical Research Data Associate